Application of nanozyme-based drug delivery systems in the treatment of ROS-related ophthalmic diseases.
4 affiliations
- 1School of Medicine, Weifang University of Science and Technology, Weifang 262700, China.
- 2School of Life Science and Technology, Shandong Second Medical University, Weifang 261053, China.
- 3Department of Dentistry, Shouguang Hospital of Traditional Chinese Medicine, Weifang 262700, China.
- 4Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China.
Abstract
ROS-related ophthalmic diseases span the ocular surface as well as the anterior and posterior segments of the eye. Dry eye disease (DED), glaucoma, diabetic retinopathy (DR) and age-related macular degeneration (AMD) have distinct anatomical targets but share common pathophysiological features, including oxidative stress, inflammation, vascular dysfunction, epithelial injury or neurodegeneration. Conventional ocular drug delivery and therapeutic modalities are hindered by severe limitations, including low bioavailability in the posterior segment of the eye and the requirement for frequent invasive administration. Nanozymes, an emerging class of therapeutic agents that integrate the properties of nanomaterials with natural enzyme-like catalytic activity, can efficiently scavenge excess reactive oxygen species (ROS) in focal lesions, modulate inflammatory factors, and remodel the pathological microenvironment, thereby providing a novel approach to the treatment of ROS-related ophthalmic diseases. This review systematically elucidates the core characteristics and therapeutic mechanisms of four major categories of nanozymes, namely metal-based, metal oxide-based, carbon-based, and composite nanozymes. To overcome physiological barriers in ocular drug delivery, such as the cornea and the blood-retinal barrier (BRB), we discuss active targeted delivery strategies based on mucin-binding retention, biomimetic cell membrane coating, and molecular ligand-mediated targeting. Furthermore, we summarize the development of intelligent and controlled-release systems in response to specific pathological microenvironments, such as ROS, pH values, and others. Additionally, this review details the latest cutting-edge applications and therapeutic efficacies of nanozymes in specific ophthalmic diseases, including AMD, DR, dry eye disease, and glaucoma. Finally, we highlight the challenges of long-term biosafety evaluation in the bench-to-bedside clinical translation of nanozymes and provide perspectives on future research directions for developing multi-stimuli-responsive synergistic nanodelivery systems.
Related
- Macrophage-Associated Delivery of Tectorigenin by MOF818 Nanozyme for the Treatment of LPS-Induced Acute Lung Injury.
- Cold‐adapted Ligninolytic Nanozyme Unveiling New Horizons in Black Liquor Treatment Under Mild Condition
- Converting Bacterial Anti-Stress Metabolites into Bactericidal Agents Using a MOF Nanozyme for Targeted Treatment of Infected Diabetic Ulcers
- An Unexpected Application of the Negative Root Arising from the Use of the Systematic Treatment of Equilibrium in Calculating pH Contribution from the Autoprotolysis of Water in Highly Diluted Strong Acid or Base Solutions
- An Unexpected Application of the Negative Root Arising from the Use of the Systematic Treatment of Equilibrium in Calculating pH contribution from the Autoprotolysis of Water in Highly Diluted Strong Acid or Base Solutions
BibTeX
@article{li2026application,
title = {{Application of nanozyme-based drug delivery systems in the treatment of ROS-related ophthalmic diseases.}},
author = {Zhipeng Li and Keda Yan and Ning Rong and Shujie Sun and Xuemin Liu and Yu Xiu and Qiusheng Zheng and Yong Sun and Jingliang Wu},
journal = {International journal of pharmaceutics: X},
year = {2026},
month = oct,
doi = {10.1016/j.ijpx.2026.100680},
url = {https://europepmc.org/article/MED/42898393},
note = {CC BY},
}
RIS
TY - JOUR
TI - Application of nanozyme-based drug delivery systems in the treatment of ROS-related ophthalmic diseases.
AU - Zhipeng Li
AU - Keda Yan
AU - Ning Rong
AU - Shujie Sun
AU - Xuemin Liu
AU - Yu Xiu
AU - Qiusheng Zheng
AU - Yong Sun
AU - Jingliang Wu
PY - 2026
DA - 2026/10/08
JO - International journal of pharmaceutics: X
DO - 10.1016/j.ijpx.2026.100680
UR - https://europepmc.org/article/MED/42898393
AB - ROS-related ophthalmic diseases span the ocular surface as well as the anterior and posterior segments of the eye. Dry eye disease (DED), glaucoma, diabetic retinopathy (DR) and age-related macular degeneration (AMD) have distinct anatomical targets but share common pathophysiological features, including oxidative stress, inflammation, vascular dysfunction, epithelial injury or neurodegeneration. Conventional ocular drug delivery and therapeutic modalities are hindered by severe limitations, including low bioavailability in the posterior segment of the eye and the requirement for frequent invasive administration. Nanozymes, an emerging class of therapeutic agents that integrate the properties of nanomaterials with natural enzyme-like catalytic activity, can efficiently scavenge excess reactive oxygen species (ROS) in focal lesions, modulate inflammatory factors, and remodel the pathological microenvironment, thereby providing a novel approach to the treatment of ROS-related ophthalmic diseases. This review systematically elucidates the core characteristics and therapeutic mechanisms of four major categories of nanozymes, namely metal-based, metal oxide-based, carbon-based, and composite nanozymes. To overcome physiological barriers in ocular drug delivery, such as the cornea and the blood-retinal barrier (BRB), we discuss active targeted delivery strategies based on mucin-binding retention, biomimetic cell membrane coating, and molecular ligand-mediated targeting. Furthermore, we summarize the development of intelligent and controlled-release systems in response to specific pathological microenvironments, such as ROS, pH values, and others. Additionally, this review details the latest cutting-edge applications and therapeutic efficacies of nanozymes in specific ophthalmic diseases, including AMD, DR, dry eye disease, and glaucoma. Finally, we highlight the challenges of long-term biosafety evaluation in the bench-to-bedside clinical translation of nanozymes and provide perspectives on future research directions for developing multi-stimuli-responsive synergistic nanodelivery systems.
SN - 2590-1567
ER -